Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 3, 2002, Pages 928-936

  Brigger, Irène ^a   Morizet, Jackie ^b   Aubert, Geneviève ^b   Chacun, Hélène ^a   Terrier Lacombe, Marie José ^b   Couvreur, Patrick ^a   Vassal, Gilles ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOACRYLATE DERIVATIVE; IMMUNOLIPOSOME; LIPOSOME; MACROGOL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; BRAIN TUMOR; CONTROLLED STUDY; ENDOTHELIUM CELL; GLIOSARCOMA; INTERSTITIUM; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN NEOPLASMS; CYANOACRYLATES; DRUG DELIVERY SYSTEMS; GLIOSARCOMA; MALE; MICROSPHERES; NANOTECHNOLOGY; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036896915     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.039669     Document Type: Article

References (37)

1. Batrakova E, Lee S, Li S, Venne A, Alakhov V, and Kabanov A (1999) Fundamental relationships between the composition of Pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm Res (NY) 16:1373-1379.
2. Brigger I, Chaminade P, Desmaële D, Peracchia MT, d'Angelo J, Gurny R, Renoir M, and Couvreur P (2000) Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology. Pharm Res (NY) 17:1124-1132.
3. Calvo P, Gouritin B, Chacun H, Desmaële D, d'Angelo J, Noël JP, Georgin D, Fattal E, Andreux JP, and Couvreur P (2001) Long-circulating Pegylated polycyanoacrylate nanoparticles as a new drug carrier for brain delivery. Pharm Res (NY) 18:1157-1166.
4. Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, Klein C, Andreux JP, and Couvreur P (2002) Quantification and localization of pegylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 15:1317-1326.
5. Colin de Verdière A, Dubernet C, Némati F, Soma E, Appel M, Ferté J, Bernard S, Puisieux F, and Couvreur P (1997) Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action, Br J Cancer 76:198-205.
6. Couvreur P, Kante B, Roland M, and Speiser P (1979) Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum, J Pharm Sci 68:1521-1524.
7. Enochs WS, Harsh G, Hochberg F, and Weissleder R (1999) Improved delineation of human brain tumors on MR images using long-circulating, superparamagnetic iron oxide agent. J Magn Resort Imaging 9:228 -232.
8. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, Steinbrecher A, Ullrich W, and Bogdahn U (2001) Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92:1936-1942.
9. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, and Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1-R4.
10. Gabizon AA (1995) Liposome circulation time and tumor targeting: Implications for cancer therapy. Adv Drug Deliv Rev 16:285-294.
11. Gerlowski LE and Jain RK (1986) Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31:288-305.
12. Groothuis DR (2000) The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro-Oncology 2:45-59.
13. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, and Jain RK (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci 95:4607-4612.
14. Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, and Chang FH (1999) Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clin Cancer Res 5:3645-3652.
15. Huwyler J, Wu D, and Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164-14169.
16. Jain RK (1998) The next frontier of molecular medicine: Delivery of therapeutics. Nat Med 4:655-657.
17. Jain RK (2001) Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function. J Control Release 74:7-25.
18. Khalifa A, Dodds D, Rampling R, Paterson J, and Murray T (1997) Liposomal distribution in malignant glioma: Possibilities for therapy. Nucl Med Commun 18:17-23.
19. Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, and Karkavitsas N (2000) High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours. Br J Cancer 83:1281-1286.
20. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65-81.
21. Lasic DD (1998) Novel applications of liposomes. Trends Biotechnol 16:307-321.
22. Lenaerts V, Couvreur P, Christiaens-Leyh D, Joiris E, Roland M, Rollman B, and Speiser P (1984) Degradation of poly(isobutylcyanoacrylate) nanoparticles. Biomaterials 5:65-68.
23. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189-207.
24. Moore A, Marecos E, Bogdanov A, and Weissleder R (2000) Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214:568-574.
25. Peracchia MT, Fattal E, Desmaële D, Besnard M, Noël JP, Gomis JM, Appel M, d'Angelo J, and Couvreur P (1999) Stealth® pegylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 60:121-128.
26. Rapoport SI, Fredericks WR, Ohno K, and Pettigrew KD (1980) Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 238:R421-R431.
27. Ritschel WA (1987) In vivo animal models for bioavailability assessment. STP Pharma Sci 3:125-141.
28. Seymour LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9:135-187.
29. Sharma US, Sharma A, Chau RI, and Straubinger RM (1997) Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res (NY) 14:992-997.
30. Siegal T, Horowitz A, and Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy. J Neurosurg 83:1029-1037.
31. Storm G, Belliot SO, Daemen T, and Lasic DD (1995) Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17:31-48.
32. Tamai I and Tsuji A (1996) Drug delivery through the blood-brain barrier. Adv Drug Deliv Rev 19:401-424.
33. Vajkoczy P and Menger MD (2000) Vascular microenvironment in gliomas. J NeuroOncol 50:99-108.
34. Weizsaecker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, and Barker M (1981) The 9L rat brain tumor: Description and application of an animal model. J Neurol 224:183-192.
35. Yuan F (1998) Transvascular drug delivery in solid tumors. Semin Radiat Oncol 8:164-175.
36. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, and Jain RK (1995) Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752-3756.
37. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, and Jain RK (1994) Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and in mouse cranial windows. Cancer Res 54:4564-4568.